CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
克服 CAR-T 细胞治疗中抗原异质性的策略
英文原题：Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy.
查看英文原题
Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）基因修饰T细胞疗法在血液系统恶性肿瘤治疗中已取得显著成功。然而，该疗法在实体瘤治疗中尚未取得突破，在血液系统肿瘤中仍面临耐药和复发问题。造成这些问题的一个主要原因是肿瘤组织的抗原异质性。本综述概述了CAR-T 细胞治疗中遇到的抗原异质性及相应的应对策略。这些策略包括使用联合治疗提高靶抗原丰度、优化CAR结构以增强对低密度抗原的敏感性、开发多靶点CAR-T 细胞，以及重编程TME以激活内源性免疫。这些方法为克服CAR-T 细胞治疗中的肿瘤抗原异质性提供了新方向。
展开英文摘要原文
Chimeric antigen receptor (CAR) gene-modified T-cell therapy has achieved significant success in the treatment of hematological malignancies.
However, this therapy has not yet made breakthroughs in the treatment of solid tumors and still faces issues of resistance and relapse in hematological cancers. A major reason for these problems is the antigenic heterogeneity of tumor tissues. This review outlines the antigenic heterogeneity encountered in CAR-T cell therapy and the corresponding strategies to address it.
These strategies include using combination therapy to increase the abundance of target antigens, optimizing the structure of CARs to enhance sensitivity to low-density antigens, developing multi-targeted CAR-T cells, and reprogramming the TME to activate endogenous immunity. These approaches offer new directions for overcoming tumor antigenic heterogeneity in CAR-T cell therapy.
论文信息
- 作者
- Zhang B、Wu J、Jiang H、Zhou M
- 单位
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200032, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Cells2025 Feb 20
- 原文标识
- PubMed 40072049 · DOI 10.3390/cells14050320
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →